European Heart Journal Cardiovascular Pharmacotherapy
Dapagliflozin did not improve heart relaxation in small trial
A heart-relaxation measure stayed at 6.2 with dapagliflozin, versus 6.6 to 6.7 with placebo, in a 32-person randomised trial.A heart-relaxation measure stayed at 6.2 with dapagliflozin, versus 6.6 to 6.7 with placebo, in a 32-person randomised trial.
Randomised trial in 29 patients with HFpEF, 13 weeks, against placeboDapagliflozin
Limit: Only 29 patients completed the protocol, limiting power to detect improved relaxation